+1-888-308-5802     
News Contact Us

Glenmark & Harbour BioMed team up, develop cancer antibodies in China

Author : Ojaswita Kutepatil | Published Date : 2018-08-08 

Mumbai-based Glenmark Pharmaceuticals has reportedly announced an exclusive license agreement with China-based Harbour BioMed. The deal, worth more than $120 million, showcases China’s willingness to transform healthcare by encouraging innovation.

Sources cite that the agreement aims at developing, producing & commercializing Glenmark’s GBR 1302 drug for the greater China region where the prevalence of certain HER2 positive cancer cases generates a clinical need.

A press release by Glenmark Pharma states that the GBR 1302 is a part of Glenmark’s patented BEAT platform and is a bispecific antibody that targets CD3 & HER2. It is utilized for the treatment of HER2 positive cancers. The drug is reportedly undergoing enrollment in the U.S. & Germany, and works by stimulating the immune system to fight against the HER2 overexpressing tumor cells.

The company would receive an upfront payment and payments on achieving certain development level, commercial & regulatory milestones, tiered royalties from Harbour BioMed on product sales.

Glenmark Chairman and MD, Glenn Saldanha expressed his delight about establishing this strategic relationship with Harbour BioMed whose extensive local experience will aid Glenmark in discovering, developing & innovating drugs for certain unfulfilled medical needs.

Harbour BioMed Founder & CEO, Dr. Jingsong Wang stated that this partnership aligns with their plan of leveraging company’s expertise in clinical development by in-licensing innovative clinical-stage products. He further added that the GBR 1302 compliments their internal portfolio of innovative antibody therapeutics.

Glenmark President and Chief Scientific Officer, Kurt Stoeckli stated that both companies follow the same principles and possess a common vision of developing highly effective & precise medicines to help cancer patients. He added that they look forward to achieving this goal together.

Post the announcement, Glenmark Pharma started trading 0.91% higher at about Rs. 602 per share, cite trusted sources.

About Author

Ojaswita Kutepatil

Ojaswita Kutepatil

Equipped with an ardent interest in writing, Ojaswita Kutepatil, a content developer by profession, presently writes articles for fractovia.org and a couple of other portals. When she isn’t harnessing the power of the pen, she loves to pursue her hobbies of cooking, reading, and crafting, to name a few. She can be contacted at- [email protected]ia.org | https://twitter.com/ojaswita_k

Related News

Go-Jek secures additional $100M in funds from Astra International

Published Date: 2019-03-05         Author: Ojaswita Kutepatil

Go-Jek, the Indonesian ride-hailing & logistics startup, is currently in the news for raising another $100 million in its ongoing Series F investment round, with the help of which the company aims to secure at least $2 billion in the long run. As per trusted sources, the latest cash influx co... Read More

Adaptive3D secures financing from latest Series A investment round

Published Date: 2019-02-06         Author: Ojaswita Kutepatil

Applied Ventures LLC and DSM Venturing led the Series A investment round.   The investment round also saw participation from Chemence & current investors that were led by late Margaret McDermott & Mary McDermott Cook. Adaptive3D Technologies (Adaptive3D), an American additiv... Read More

Uber Eats to pilot Coles’ ready-to-eat meals in a new partnership deal

Published Date: 2019-01-29         Author: Ojaswita Kutepatil

The supermarket giant Coles has teamed up with Uber Eats to test-launch meal delivery services across Australia Uber Eats, an American online food delivery platform, and Australian supermarket chain Coles, have reportedly signed a partnership agreement for meal delivery to customers. Under the pa... Read More

© 2019 Fractovia. All Rights Reserved